Enovis (ENOV)
NYSE:ENOV
Top Page
Enovis
(NYSE:ENOV)
Select Model
Select Model
Rating:52Neutral
Price Target:
$23.00
▼(-1.58% Downside)
Action:ReiteratedDate:02/27/26
Score is held back primarily by weak recent profitability (large losses/very negative ROE) despite strong revenue growth, plus a technically soft chart. Offsetting factors include improved cash flow versus 2024, lower leverage, and constructive 2026 guidance for growth, earnings, and cash conversion; valuation support is limited due to the negative P/E and no dividend.
Positive Factors
Sustained revenue growth
Multi-year top-line expansion demonstrates durable demand across Enovis’s Prevention & Recovery and Reconstructive franchises. Consistent revenue growth provides scale to fund R&D, commercial expansion and integration costs, reducing single-product risk and supporting long-term margin recovery and reinvestment.
Negative Factors
Severe profitability deterioration
Despite strong revenue and gross margins, large net losses and very negative ROE signal that the company is not yet converting sales into sustainable shareholder returns. Persistent negative profitability can impair reinvestment, raise refinancing risk and pressure long-term capital allocation decisions.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained revenue growth
Multi-year top-line expansion demonstrates durable demand across Enovis’s Prevention & Recovery and Reconstructive franchises. Consistent revenue growth provides scale to fund R&D, commercial expansion and integration costs, reducing single-product risk and supporting long-term margin recovery and reinvestment.
Read all positive factors
Enovis (ENOV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.34B
Dividend YieldN/A
Average Volume (3M)1.09M
Price to Earnings (P/E)―
Beta (1Y)1.44
Revenue Growth11.57%
EPS Growth-1016.39%
CountryUS
Employees7,367
SectorHealthcare
Sector Strength45
IndustryIndustrial - Machinery
Share Statistics
EPS (TTM)0.95
Shares Outstanding57,245,132
10 Day Avg. Volume950,198
30 Day Avg. Volume1,090,008
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.02
Price to Sales (P/S)0.67
P/FCF Ratio75.96
Enterprise Value/Market Cap2.00
Enterprise Value/Revenue1.19
Enterprise Value/Gross Profit1.99
Enterprise Value/Ebitda-3.26
Forecast
1Y Price Target
$45.83Price Target Upside96.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)3.52
Revenue Forecast (FY)$2.34B
Enovis Business Overview & Revenue Model
Company Description
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical ther...
How the Company Makes Money
Enovis makes money primarily by selling medical devices and related solutions used across musculoskeletal care. Its key revenue streams include: (1) Prevention & Recovery product sales—revenue from orthopedic bracing/supports and rehabilitation-fo...
Enovis Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The call presents a predominantly positive operational and financial story: sustainable organic growth (6% full‑year), strong Recon performance (8% organic; 10% international), margin expansion at the gross level (+170 bps), a return to positive free cash flow and improved leverage/interest expense. Management also highlighted a robust innovation pipeline and actionable 2026 guidance that targets continued growth and improved cash conversion. Notable negatives include a sizeable $501M goodwill impairment, tariff impacts (~$15M), execution shortcomings in Q4 (4 fewer selling days / admitted missed execution), and ongoing integration and investment costs (including a $41M revenue headwind from the Dr. Comfort divestiture). On balance, the material positives around growth, margins, cash flow improvement, portfolio momentum and a clear 2026 outlook outweigh the lowlights, though shareholders should monitor the implications of the impairment, tariff exposure and near‑term operational cadence.Positive Updates
Full-Year Organic Revenue Growth
Full-year 2025 sales of $2.2B (+7% reported) with 6% organic revenue growth; Recon organic growth of 8% and Prevention & Recovery (P&R) organic growth of 4%.
Negative Updates
Material Goodwill Impairment
Recorded a noncash goodwill impairment of $501M in Q4 2025 after reviewing market capitalization vs carrying values. Management states this has no impact on liquidity, cash flows or debt covenants, but it is a significant accounting charge.
Read all updates
Q4-2025 Updates
Positive
Negative
Full-Year Organic Revenue Growth
Full-year 2025 sales of $2.2B (+7% reported) with 6% organic revenue growth; Recon organic growth of 8% and Prevention & Recovery (P&R) organic growth of 4%.
Read all positive updates
Company Guidance
Enovis guided 2026 revenues of $2.31–$2.37 billion, implying mid‑single‑digit organic growth of 4%–6% (driven by high‑single‑digit Recon growth and low‑single‑digit P&R growth), with a +0.5%–1.5% FX tailwind and a $41 million revenue headwind from the Dr. Comfort divestiture; adjusted EBITDA is expected to be $425–$435 million (about a 50 bp margin improvement vs. 2025), depreciation $118–$122 million, interest and other $30–$32 million, and an adjusted tax rate of ~23%. Management plans a share count of ~59 million and adjusted EPS of $3.52–$3.73, targets free cash flow conversion of 25%+ of adjusted net income in 2026 (on the path toward a long‑term 70%–80% conversion), and expects to continue deleveraging from ~3.1x toward below 3x while investing to complete Lima integration.Enovis Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
55
Neutral
Cash Flow
46
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.25B | 2.11B | 1.71B | 1.56B | 1.43B |
| Gross Profit | 1.35B | 1.18B | 990.78M | 869.38M | 777.67M |
| EBITDA | -830.22M | -481.03M | 169.73M | 241.69M | 170.25M |
| Net Income | -1.18B | -825.49M | -33.26M | -13.29M | 71.66M |
Balance Sheet | |||||
| Total Assets | 3.83B | 4.72B | 4.51B | 4.27B | 8.52B |
| Cash, Cash Equivalents and Short-Term Investments | 36.39M | 48.17M | 36.19M | 24.30M | 680.25M |
| Total Debt | 1.38B | 1.40B | 536.42M | 334.82M | 2.16B |
| Total Liabilities | 2.34B | 2.15B | 1.09B | 823.45M | 3.85B |
| Stockholders Equity | 1.49B | 2.56B | 3.42B | 3.45B | 4.62B |
Cash Flow | |||||
| Free Cash Flow | 19.92M | -67.21M | 12.77M | -161.31M | 251.86M |
| Operating Cash Flow | 217.29M | 113.50M | 134.99M | -55.86M | 356.10M |
| Investing Cash Flow | -179.37M | -955.47M | -242.47M | -176.39M | -320.48M |
| Financing Cash Flow | -52.40M | 846.82M | 127.80M | -465.13M | 584.91M |
Enovis Technical Analysis
Negative
23.37
Price Trends
23.16
Negative
25.81
Negative
28.31
Negative
Market Momentum
-0.37
Positive
45.39
Neutral
31.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENOV, the sentiment is Negative. The current price of 23.37 is below the 20-day moving average (MA) of 23.88, above the 50-day MA of 23.16, and below the 200-day MA of 28.31, indicating a bearish trend. The MACD of -0.37 indicates Positive momentum. The RSI at 45.39 is Neutral, neither overbought nor oversold. The STOCH value of 31.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENOV.
Enovis Risk Analysis
Enovis disclosed 41 risk factors in its most recent earnings report. Enovis reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Enovis Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $3.10B | 308.57 | 7.68% | 0.57% | 18.51% | -28.69% | |
67 Neutral | $2.17B | 37.53 | 3.75% | 0.64% | -1.46% | -10.03% | |
53 Neutral | $1.82B | 32.79 | 21.10% | 0.10% | 3.91% | 1.48% | |
52 Neutral | $1.34B | -0.73 | -54.42% | ― | 11.57% | -1016.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $2.12B | -48.93 | -21.90% | ― | 22.40% | -18.99% |
* Healthcare Sector Average
ENOV
Enovis
23.37
-15.51
-39.89%
EPAC
Enerpac Tool Group
34.54
-11.63
-25.19%
SXI
Standex International
255.52
89.03
53.47%
HLIO
Helios Technologies
65.69
31.96
94.78%
XMTR
Xometry
40.98
14.38
54.06%
Enovis Corporate Events
Business Operations and Strategy
Enovis to Present at J.P. Morgan Healthcare Conference
Positive
Jan 12, 2026
Enovis Corporation announced that its management team would present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 4:30 p.m. PST (7:30 p.m. EST). The company made the presentation accessible to investors and o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.